

Antiviral Drugs Market 2026

<https://marketpublishers.com/r/AFE360701A30EN.html>

Date: November 2025

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: AFE360701A30EN

Abstracts

The Antiviral Drugs Market was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Antiviral Drugs Market.

This report delivers a comprehensive overview of the Antiviral Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Antiviral Drugs Market. The Antiviral Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Antiviral Drugs Market Scope:

By Drug Class

Reverse Transcriptase Inhibitors

DNA Polymerase Inhibitors

Protease Inhibitors

Neuraminidase Inhibitors

Other

By Type

Branded

Generic

By Application

HIV

Hepatitis

Herpes

Influenza

Others

By End User

Hospitals

Clinics

Ambulatory Surgical Centers

Key Players

Gilead Sciences

F. Hoffmann-La Roche AG

GlaxoSmithKline plc

AbbVie

Merck & Co., Inc.

Johnson & Johnson Services, Inc.

Bristol-Myers Squibb Company

Cipla Inc.

Aurobindo Pharma

Dr. Reddy's Laboratories Ltd.(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Antiviral Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Antiviral Drugs Market. The Antiviral Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest

of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the

privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet by Drug Class
- 3.2. Market snippet by Type
- 3.3. Market snippet by Application
- 3.4. Market Snippet by End User
- 3.5. Market Snippet by Region

4. MARKET DYNAMICS

- 4.1. Market Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing viral infection incidences and the rising R&D activities
 - 4.1.1.2. Development of new mechanisms and research on second-generation molecules
 - 4.1.2. Restraints:
 - 4.1.2.1. High cost and alternate medicine is likely to hinder the market growth
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Unmet Needs

6. COVID-19 ANALYSIS

- 6.1. Analysis of Covid-19 on the Market
 - 6.1.1. Before COVID-19 Market Scenario
 - 6.1.2. Present COVID-19 Market Scenario
 - 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY DRUG CLASS

- 7.1. Introduction
 - 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
 - 7.1.2. Market Attractiveness Index, By Drug Class Segment
- 7.2. Reverse Transcriptase Inhibitors*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
 - 7.2.3. Nucleoside Reverse transcriptase inhibitors (NRTIs)
 - 7.2.4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
- 7.3. DNA Polymerase Inhibitors
- 7.4. Protease Inhibitors
- 7.5. Neuraminidase Inhibitors
- 7.6. Other

8. BY TYPE

- 8.1. Introduction
 - 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
 - 8.1.2. Market Attractiveness Index, By Type
- 8.2. Branded*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
- 8.3. Generic

9. BY APPLICATION

9.1. Introduction

9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

9.1.2. Market Attractiveness Index, By Application

9.2. HIV *

9.2.1. Introduction

9.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028

9.3. Hepatitis

9.4. Herpes

9.5. Influenza

9.6. Others

10. BY END USER

10.1. Introduction

10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment

10.1.2. Market Attractiveness Index, By End User Segment

10.2. Hospitals *

10.2.1. Introduction

10.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028

10.3. Clinics

10.4. Ambulatory Surgical Centers

11. BY REGION

11.1. Introduction

11.1.1. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region

11.1.2. Market Attractiveness Index, By Region

11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.2.7.1. U.S.

11.2.7.2. Canada

11.2.7.3. Mexico

11.3. Europe

11.3.1. Introduction

11.3.2. Key Region-Specific Dynamics

11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

Distribution Channel

11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.3.7.1. Germany

11.3.7.2. U.K.

11.3.7.3. France

11.3.7.4. Italy

11.3.7.5. Spain

11.3.7.6. Rest of Europe

11.4. South America

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.4.7.1. Brazil

11.4.7.2. Argentina

11.4.7.3. Rest of South America

11.5. Asia Pacific

11.5.1. Introduction

11.5.2. Key Region-Specific Dynamics

11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.5.7.1. China

11.5.7.2. India

11.5.7.3. Japan

11.5.7.4. Australia

11.5.7.5. Rest of Asia Pacific

11.6. Middle East and Africa

11.6.1. Introduction

11.6.2. Key Region-Specific Dynamics

11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. COMPETITIVE LANDSCAPE

12.1. Key Developments and Strategies

12.2. Company Share Analysis

12.3. Product Benchmarking

12.4. List of key companies to watch

12.5. List of the company with disruptive technology

12.6. List of start-up companies

13. COMPANY PROFILES

13.1. Gilead Sciences *

13.1.1. Company Overview

13.1.2. Product Portfolio and Description

13.1.3. Key Highlights

13.1.4. Financial Overview

13.2. F. Hoffmann-La Roche AG

13.3. GlaxoSmithKline plc

13.4. AbbVie

13.5. Merck & Co., Inc.

13.6. Johnson & Johnson Services, Inc.

13.7. Bristol-Myers Squibb Company

13.8. Cipla Inc.

13.9. Aurobindo Pharma

13.10. Dr. Reddy's Laboratories Ltd. (*LIST NOT EXHAUSTIVE)

14. DATAM INTELLIGENCE

- 14.1. Appendix
- 14.2. About Us and Services
- 14.3. Contact Us

I would like to order

Product name: Antiviral Drugs Market 2026

Product link: <https://marketpublishers.com/r/AFE360701A30EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AFE360701A30EN.html>